{"entity":{"id":"richard-gray","kind":"person","name":"Richard Gray","aka":[],"tldr":"Statistician behind the Early Breast Cancer Trialists' meta-analyses that set the global evidence base for adjuvant therapy.","summary":"Richard Gray leads the secretariat of the Early Breast Cancer Trialists' Collaborative Group, whose individual-patient-data meta-analyses of hundreds of trials quantified the benefits of tamoxifen, aromatase inhibitors, chemotherapy, radiotherapy and bisphosphonates and underpin every breast cancer guideline. He also led the QUASAR colorectal adjuvant trials and the aTTom trial of ten years of tamoxifen.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gray%20R%5BAuthor%5D%20EBCTCG%20breast"}],"tags":["meta-analysis","biostatistics","breast"],"related":[],"cancers":["breast-hr-positive","colorectal"],"sections":[],"technologies":["endocrine-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":["oxford-cancer"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medical Statistics, Nuffield Department of Population Health, University of Oxford; Secretariat, EBCTCG","institutionId":"oxford-cancer","specialisms":["Meta-analysis","Breast cancer adjuvant therapy","Large simple trials","Biostatistics"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gray%20R%5BAuthor%5D%20EBCTCG%20breast"}],"papers":[{"title":"Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials","journal":"Lancet","year":2005,"doi":"10.1016/S0140-6736(05)66544-0"},{"title":"Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials","journal":"Lancet","year":2015,"doi":"10.1016/S0140-6736(15)61074-1"}],"orcid":"0000-0003-4440-574X"},"route":"/people/richard-gray/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"}],"technology":[{"id":"endocrine-therapy","kind":"technology","name":"Endocrine therapy (SERMs, AIs, SERDs)","route":"/technologies/endocrine-therapy/"}],"institution":[{"id":"oxford-cancer","kind":"institution","name":"Oxford Cancer (Oxford University Hospitals and University of Oxford)","route":"/institutions/oxford-cancer/"}],"paper":[{"id":"paper-quasar-adjuvant-chemotherapy-vs-observation-lancet-2007","kind":"paper","name":"Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study (QUASAR)","route":"/key-papers/paper-quasar-adjuvant-chemotherapy-vs-observation-lancet-2007/"}]}}